Company Profile
BriaCell Stock Price, News & Catalysts
- Ticker:
- BCTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
4.11 USD (-3.97%)
Close
Last updated: October 1, 2026
23.7M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, BCTX closed down 3.97% at $4.11. No new same-company headline was identified in the current news window.
Company overview
Cancer Immunotherapy Developer
BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents.
Bria-IMT in Metastatic Breast Cancer
Bria-IMT is an off-the-shelf whole-cell immunotherapy being evaluated with checkpoint blockade in metastatic breast cancer. The program has advanced into a pivotal Phase 3 study for patients who have exhausted multiple prior treatment options.
Personalized Off-the-Shelf Platform
The Bria-OTS and Bria-BRES approaches use a bank of engineered cell lines selected according to patient immune characteristics. This design seeks to preserve personalization while avoiding the manufacturing time required for fully patient-specific cell therapies.
Bria-BRES and Bria-PROS Expansion
Bria-BRES is being developed for breast cancer through a next-generation clinical program, while Bria-PROS extends the platform into prostate cancer. These programs broaden the company's pipeline beyond the lead Bria-IMT regimen.
Combination-Oriented Development
BriaCell's strategy is to pair its cellular immunotherapies with checkpoint inhibitors and other agents that may reinforce antitumor immune activity. The company retains responsibility for clinical development while using external manufacturing and clinical partners.
Biomarker-Guided Patient Selection
Clinical and translational work evaluates immune signatures and tumor characteristics associated with response. These biomarkers may help define the patients most likely to benefit from BriaCell's cellular regimens.
Future catalysts
- Initiation of the Phase 1/2a study of Bria-BRES+ following FDA clearance of the IND.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BriaCell (BCTX)?
BriaCell (BCTX) most recently closed at 4.11 USD, a -3.97% move versus the previous session.
What is the market cap of BriaCell (BCTX)?
BriaCell currently has a market capitalization of 23.7M USD on BioPharmSignal.
What does BriaCell do?
Cancer Immunotherapy Developer BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents. Bria-IMT in Metastatic Breast Cancer Bria-IMT is an off-the-shelf whole-cell immunotherapy being...
On which exchange is BCTX stock listed?
BriaCell (BCTX) is associated with NASDAQ, Canada, Biopharma.
What is Cancer?
Cancer Immunotherapy Developer BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer.
Which conditions is BriaCell targeting with Cancer?
BriaCell is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does BriaCell describe recent progress with Cancer?
Initiation of the Phase 1/2a study of Bria-BRES+ following FDA clearance of the IND.
What is Immunotherapy?
Cancer Immunotherapy Developer BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer.